{"id":"alirocumab-injectable-product","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Musculoskeletal pain"},{"rate":"null","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2109540","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting PCSK9, alirocumab reduces the degradation of low-density lipoprotein receptors on the liver surface, leading to increased clearance of low-density lipoprotein cholesterol from the bloodstream. This results in a decrease in the levels of low-density lipoprotein cholesterol in the blood, which can help to reduce the risk of cardiovascular events.","oneSentence":"Alirocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) to lower low-density lipoprotein cholesterol.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:53.494Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of adults with primary hypercholesterolemia or mixed dyslipidemia as an adjunct to diet and other lipid-lowering treatments, or alone if the only lipid-lowering treatment is statin therapy."}]},"trialDetails":[{"nctId":"NCT03542110","phase":"PHASE4","title":"The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial","status":"TERMINATED","sponsor":"Minneapolis Heart Institute Foundation","startDate":"2018-08-04","conditions":"Saphenous Vein Graft Atherosclerosis","enrollment":46},{"nctId":"NCT02957682","phase":"PHASE4","title":"Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-11-02","conditions":"Hypercholesterolemia","enrollment":2176},{"nctId":"NCT03507374","phase":"EARLY_PHASE1","title":"PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis","status":"TERMINATED","sponsor":"University of Utah","startDate":"2018-10-30","conditions":"Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage","enrollment":20},{"nctId":"NCT02992301","phase":"PHASE4","title":"Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab","status":"UNKNOWN","sponsor":"Westside Medical Associates of Los Angeles","startDate":"2016-11","conditions":"Atherosclerosis, Hyperlipidemia","enrollment":35},{"nctId":"NCT03634293","phase":"PHASE2, PHASE3","title":"Treatment of Severe Infection With Antihyperlipidemia Drug","status":"UNKNOWN","sponsor":"Wolfson Medical Center","startDate":"2019-01","conditions":"Sepsis, Septic Shock","enrollment":712},{"nctId":"NCT02023879","phase":"PHASE3","title":"Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-12-16","conditions":"Hypercholesterolemia","enrollment":233},{"nctId":"NCT01954394","phase":"PHASE3","title":"Open Label Study of Long Term Safety Evaluation of Alirocumab","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-12-17","conditions":"Hypercholesterolemia","enrollment":986},{"nctId":"NCT02585778","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-10-23","conditions":"Hypercholesterolaemia","enrollment":517},{"nctId":"NCT02642159","phase":"PHASE4","title":"Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-03-15","conditions":"Dyslipidemia","enrollment":413}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Praluent"],"phase":"phase_2","status":"active","brandName":"Alirocumab Injectable Product","genericName":"Alirocumab Injectable Product","companyName":"Wolfson Medical Center","companyId":"wolfson-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alirocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) to lower low-density lipoprotein cholesterol. Used for Treatment of adults with primary hypercholesterolemia or mixed dyslipidemia as an adjunct to diet and other lipid-lowering treatments, or alone if the only lipid-lowering treatment is statin therapy..","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}